|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma显示文摘AIM: To define NGF (nerve growth factor) and its high- affinity receptor trkANGF presence and distribution in fibrotic liver and in HCC, and to verify if NGF might have a role in fibrosis and HCC. METHODS: Intracellular distribution of NGF and trkANGF were assessed by immunohistochemistry and immuno- electron microscopy in liver specimens from HCC, cirrhosis or both. ELISA was used to measure circulating NGF levels. RESULTS: NGF and trkANGF were highly expressed in HCC tissue, mainly localized in hepatocytes, endothelial and some Kupffer cells. In the cirrhotic part of the liver they were also markedly expressed in bile ducts epithelial and spindle-shaped cells. Surprisingly, in cirrhotic tissue from patients without HCC, both NGF and trkANGF were negative. NGF serum levels in cirrhotic and/or HCC patient were up to 25-fold higher than in controls. CONCLUSION: NGF was only detected in liver tissue with HCC present. Intracellular distribution suggests paracrine and autocrine mechanisms of action. Better definition of mechanisms may allow for therapeutic and diagnostic/prognostic use of NGF. | Guido Rasi Annalucia Serafino Lia Bellis Maria Teresa Lonardo Federica Andreola Manuela Zonfrillo Giovanni Vennarecci Pasquale Pierimarchi Paola Sinibaldi Vallebona Giuseppe Maria Ettorre Eugenio Santoro Claudio Puoti | 2007 | World Journal of Gastroenterology2007，13，37： | 13 |
| 2 | Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease显示文摘Concomitantly with the increase in the prevalences of overweight/obesity, nonalcoholic fatty liver disease(NAFLD) has worldwide become the main cause of chronic liver disease in both adults and children. Patients with fatty liver display features of metabolic syndrome(Met S), like insulin resistance(IR), glucose intolerance, hypertension and dyslipidemia. Recently, epidemiological studies have linked obesity, Met S, and NAFLD to decreased bone mineral density and osteoporosis, highlighting an intricate interplay among bone, adipose tissue, and liver. Osteoprotegerin(OPG), an important symbol of the receptor activator of nuclear factor-B ligand/receptor activator of nuclear factor kappa B/OPG system activation, typically considered for its role in bone metabolism, may also play critical roles in the initiation and perpetuation of obesityrelated comorbidities. Clinical data have indicated that OPG concentrations are associated with hypertension, left ventricular hypertrophy, vascular calcification, endothelial dysfunction, and severity of liver damage in chronic hepatitis C. Nonetheless, the relationship between circulating OPG and IR as a key feature of Met S as well as between OPG and NAFLD remains uncertain. Thus, the aims of the present review are to provide the existent knowledge on these associations and to discuss briefly the underlying mechanisms linking OPG and NAFLD. | Lucia Pacifico Gian Marco Andreoli Miriam D'Avanzo Delia De Mitri Pasquale Pierimarchi | 2018 | World Journal of Gastroenterology2018，24，19： | 11 |
| 3 | Genetic immunization with CDR3 - based fusion vaccine confers protection and long - term tumor - free survival in a mouse model of lympho- ma显示文摘 | IURESCIA S FIORETTI D PIERIMARCHI P | 2010 | J Biomed Biotechnol2010，2010，31： | 1 |
| 4 | Combination therapy in the treatment of chronic viral hepatatitis and prevention of hepatocellular carcinoma 显示文摘 | Rasi G Pierimarchi P Sinibaldi Vallebona P | 2003 | Int Immunopharmacol2003，3，8： | 1 |
| 5 | Efficacy of repeated cycles of chemo-immunotherapy with Thymosin α1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery显示文摘 | Gianfranco Silecchia Enrico Guarino Paola Sinibaldi-Vallebona Pasquale Pierimarchi Angelo Restuccia Erasmo Spaziani Paola Bernard Cynthia Tuthill Enrico Garaci Guido Rasi | 1999 | Cancer Immunology, Immunotherapy1999，，4： | 1 |
| 6 | Thymosinα1 as a stimulatoryagent of innate cell-mediated immune response显示文摘 | Serafino A Pierimarchi P Pica F | 2012 | Ann N Y AcadSci2012，1270，： | 1 |
| 7 | Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 显示文摘 | Rasi G Pierimarchi P Sinibaldi Vallebona P | 2003 | Int Immunopharmacol2003，3，8： | 1 |
| 8 | Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma显示文摘 | Rasi G Pierimarchi P Sinibaldi Vallebona P | 2003 | Int Immunopharmacol2003，3，8： | 1 |
| 9 | Thymosin ctl as a stimu-latory agent of innate cell-mediated immune response 显示文摘 | Serafino A Pierimarchi P Pica F | 2012 | Ann NY ACAD SCI2012，1270，1： | 1 |
| 10 | Combination Therapy in the Treatment of Chronic Viral Hepatitis and Prevention of Hepatocellular Carcinoma显示文摘 | Rasi G Pierimarchi P Sinibaldi Vallebona P | 2003 | Int Immunopharmacol2003，3，8： | 1 |
| 11 | Combination threapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma显示文摘 | Rasi G Pierimarchi P Sinibaldi Vallebona P | 2003 | Int Immunopharmacol2003，3，8： | 1 |
| 12 | Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats显示文摘 | Sinibaldi Vallebona P Rasi G Pierimarchi P | 2004 | Int J Cancer2004，110，1： | 1 |
| 13 | Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs:nuclear and cytoplasmic triggering?显示文摘 | Serafino A Sinibaldi VP Pierimarchi P | 1999 | Anticancer Res1999，19，3： | 1 |
| 14 | Thymosin alpha 1 as astimulatory agent of innate cell-mediated immune response显示文摘 | Serafino A Pierimarchi P Pica F | 2012 | Ann NY Acad Sci2012，1270，： | 1 |
| 15 | Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 显示文摘 | RASI G PIERIMARCHI P SINIBALDI VALLEBONA P | 2003 | Int Immunopharmacol2003，3，8： | 1 |
| 16 | Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 显示文摘 | Rasi G Pierimarchi P Sinibaldi Vallebona P | 2003 | Int Immunopharmacol2003，3，8： | 1 |
| 17 | Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma显示文摘 | Rasi G Pierimarchi P Sinibaldival lebona P | | 0，，08： | 1 |
| 18 | Vaccination with a synthetic nonapeptide expressed in human tumors prevents eoloreetal cancer liver metastases in syngeneic rats显示文摘 | Sinibaldi Vallebona P Rasi G Pierimarchi P | 2004 | Int J Cancer2004，110，1： | 1 |
| 19 | Combination therapy in the treatment of chronic viral hepatitis and pervention of hepa- tocellular carcinoma 显示文摘 | Rasi G Pierimarchi P Sinibaldi Vallebona P | 2003 | Int Immunopharma- col2003，3，： | 1 |
| 20 | Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma显示文摘 | Rasi G Pierimarchi P Sinihaldi Vallebona P | 2003 | Int Immuno-pharmacol2003，3，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员